Pennsylvania is currently home to 3474 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
NRF for Improved Re-Entry Outcomes for Offenders With Brain Injury (Brain Injury RE)
NCT05708092
Recruiting
The purpose of this study is to evaluate the effectiveness of NeuroResource Facilitation, a novel/innovative intervention, in reducing recidivism in offenders with brain injury (BI).
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Brain Injury Association of Pennsylvania, Carlisle, Pennsylvania
Conditions: Brain Injury
Register for Updates
Development of 3DMPUS as a Decision Support Tool for Patients With Liver Tumors Undergoing Therapy
NCT05705219
Recruiting
This clinical trial studies how well 3-dimensional multi-parametric ultrasound (3D MPUS) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. Continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response. 3D-MPUS is an inexpensive and safe method, which may provide complementary quantitative functional (perfusion) and tissue characterization information to anatomical radiological assessment or blood biom... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Thomas Jefferson Hospital, Philadelphia, Pennsylvania
Conditions: Liver Cancer, Adult
Register for Updates
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219
Recruiting
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Primary Immune Thrombocytopenia
Register for Updates
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Recruiting
This is an international, multicenter study with two components: Registry A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection Enrollment is open to all genes on the RD Rare Gene List Natural History Study A prospective, standardized, longitudinal Natural History Study Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows. Registry Objectives Genotype Characterization Cro... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
05/01/2024
Locations: Center for Advanced Retinal and Ocular Therapeutics, Philadelphia, Pennsylvania
Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Register for Updates
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
NCT05588648
Recruiting
MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 14 years of age and older who meet the criteria for study enrollment.
Gender:
All
Ages:
14 years and above
Trial Updated:
05/01/2024
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Osteosarcoma
Register for Updates
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766
Recruiting
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Gastrointestinal Tract Malignancies
Register for Updates
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
NCT05263999
Recruiting
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids
Gender:
All
Ages:
12 years and above
Trial Updated:
05/01/2024
Locations: University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
Register for Updates
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
NCT05239624
Recruiting
This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to have surgery to remove their cancer (cystectomy). The researchers will look at whether treatment with enfortumab vedotin and pembrolizumab before surgery can get rid of cancer within the lymph nodes. They will also try to find out if this combination of drugs is effective at shrinking participants' c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Lehigh Valley Health Network (Data Collection Only), Allentown, Pennsylvania
Conditions: Urothelial Carcinoma
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Stage III Colon Cancer
Register for Updates
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728
Recruiting
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University of Pittsburgh University of Pittsburgh 2, Pittsburgh, Pennsylvania
Conditions: Glioblastoma
Register for Updates
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Consultants in Medical Oncology & Hematology, Broomall, Pennsylvania
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Register for Updates
INSPIRE Pipeline™ Shield Post Approval Study
NCT05071963
Recruiting
The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States.
Gender:
All
Ages:
22 years and above
Trial Updated:
05/01/2024
Locations: Geisinger Medical Center, Danville, Pennsylvania
Conditions: Intracranial Aneurysm
Register for Updates